Select treatment outcomes in HSTCL (>2 patients)
| Reference . | N . | Treatment . | Transplant . | Response . | Outcomes . |
|---|---|---|---|---|---|
| Foss et al5 | 31 | Nonanthracycline 40% | auto (1) | 40% CR | Median survival 13 mo |
| Anthracycline 60% | allo (7: 4 in CR1, 3 in salvage) | 3-y OS 40% | |||
| 3-y PFS 40% | |||||
| Yabe et al12 | 27 | HyperCVAD (15) | autoSCT (7) | CR (4) | Median OS of 28.3 mo |
| CHOP-like (9) | alloSCT (5) | SCT receipt associated with longer EFS but not OS | |||
| Other (19) | All patients eventually DOD | ||||
| Pentostatin (6) | |||||
| Alemtuzumab (6) | |||||
| Belhadj et al21 | 21 | CHOP/CHOP-like (19) | autoSCT (6) | CR (11) | All patients DOD except 2 treated with platinum agents (and autoSCT) |
| Platinum/Ara-C (2) | alloSCT (2) | PR (2) | |||
| PD (6) | |||||
| PR (2) | |||||
| Falchook et al20 | 15 | CHOP/CHOP-like (6) | autoSCT (5) | 50% CR (7 of 14 receiving chemotherapy) | Median duration of CR of 8 mo |
| HyperCVIDDMTX/Ara-C (4) | alloSCT (2) | All patients who received SCT are alive and in CR | |||
| Other (4) | |||||
| Voss et al46 | 14 | CHOP (4) | autoSCT (4) | 1 CR, 2 PR, 1 PD | 7 remain alive (median f/u 65.6 mo) |
| ICE/IVAC (8) | alloSCT (8) | 4 CR, 2 PR, 2 PD | 6 of 7 alive had non-CHOP and SCT | ||
| Pentostatin/2-CDA (2) | 2 PD | ||||
| Macon et al16 | 14 | None (5) | autoSCT (2) | N/A | Median OS 6 mo |
| CHOP (2) | 11 DOD, 8 within a year of diagnosis | ||||
| HDT + auto-SCT (2) | 2 long-term remission: 1 after autoSCT, 1 after intensive regimen | ||||
| Other intensive chemotherapy (2) | |||||
| Yabe et al8 | 7 | CHOP-like (4) | auto (1) | N/A | 4 alive (f/u 1-86 mo) |
| HyperCVAD-like (3) | allo (2) | 3 of 4 alive had SCT | |||
| Hassan et al68 | 7 | CHOP (1) | None | PD (1) | All DOD |
| Saito et al69 | 3 | LSG9 (1) | None | CR (1) | All DOD <9 mo |
| CHOP + ESHAP (1) | PD (1) | ||||
| CHOP (1) | CR (1) | ||||
| Rashidi and Cashen57 | 44 | alloSCT, TBI-based conditioning 71% | allo (44) | Pre-alloSCT response | 42% 3-y RFS |
| 41% CR | 56% 3-y OS | ||||
| 43% PR | |||||
| 16% PD |
| Reference . | N . | Treatment . | Transplant . | Response . | Outcomes . |
|---|---|---|---|---|---|
| Foss et al5 | 31 | Nonanthracycline 40% | auto (1) | 40% CR | Median survival 13 mo |
| Anthracycline 60% | allo (7: 4 in CR1, 3 in salvage) | 3-y OS 40% | |||
| 3-y PFS 40% | |||||
| Yabe et al12 | 27 | HyperCVAD (15) | autoSCT (7) | CR (4) | Median OS of 28.3 mo |
| CHOP-like (9) | alloSCT (5) | SCT receipt associated with longer EFS but not OS | |||
| Other (19) | All patients eventually DOD | ||||
| Pentostatin (6) | |||||
| Alemtuzumab (6) | |||||
| Belhadj et al21 | 21 | CHOP/CHOP-like (19) | autoSCT (6) | CR (11) | All patients DOD except 2 treated with platinum agents (and autoSCT) |
| Platinum/Ara-C (2) | alloSCT (2) | PR (2) | |||
| PD (6) | |||||
| PR (2) | |||||
| Falchook et al20 | 15 | CHOP/CHOP-like (6) | autoSCT (5) | 50% CR (7 of 14 receiving chemotherapy) | Median duration of CR of 8 mo |
| HyperCVIDDMTX/Ara-C (4) | alloSCT (2) | All patients who received SCT are alive and in CR | |||
| Other (4) | |||||
| Voss et al46 | 14 | CHOP (4) | autoSCT (4) | 1 CR, 2 PR, 1 PD | 7 remain alive (median f/u 65.6 mo) |
| ICE/IVAC (8) | alloSCT (8) | 4 CR, 2 PR, 2 PD | 6 of 7 alive had non-CHOP and SCT | ||
| Pentostatin/2-CDA (2) | 2 PD | ||||
| Macon et al16 | 14 | None (5) | autoSCT (2) | N/A | Median OS 6 mo |
| CHOP (2) | 11 DOD, 8 within a year of diagnosis | ||||
| HDT + auto-SCT (2) | 2 long-term remission: 1 after autoSCT, 1 after intensive regimen | ||||
| Other intensive chemotherapy (2) | |||||
| Yabe et al8 | 7 | CHOP-like (4) | auto (1) | N/A | 4 alive (f/u 1-86 mo) |
| HyperCVAD-like (3) | allo (2) | 3 of 4 alive had SCT | |||
| Hassan et al68 | 7 | CHOP (1) | None | PD (1) | All DOD |
| Saito et al69 | 3 | LSG9 (1) | None | CR (1) | All DOD <9 mo |
| CHOP + ESHAP (1) | PD (1) | ||||
| CHOP (1) | CR (1) | ||||
| Rashidi and Cashen57 | 44 | alloSCT, TBI-based conditioning 71% | allo (44) | Pre-alloSCT response | 42% 3-y RFS |
| 41% CR | 56% 3-y OS | ||||
| 43% PR | |||||
| 16% PD |
2-CDA, cladribine; allo, allogeneic; auto, autologous; CR1, first complete response; DOD, died of disease; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin; f/u, follow-up; HyperCVAD cyclophosphamide, vincristine, doxorubicin, and dexamethasone; HyperCVIDDMTX/Ara-C, fractionated cyclophosphamide, liposomal doxorubicin, dexamethasone, vincristine, methotrexate, cytarabine; ICE, ifosfamide, carboplatin, etoposide; IVAC, ifosfamide, etoposide, cytarabine; LSG9, VEPA-B/FEPP-AB/M-FEPA; N/A, not applicable; PD, progressive disease; PFS, progression-free survival; PR, partial response; RFS, relapse-free survival; TBI total-body irradiation.